Navigate to
-
Cover for 2023 October Quarterly Pipeline A view into upcoming specialty & traditional drugs Prime Therapeutics https://issuu.com/primetherapeutics/docs/2023_pipeline_oct?fr=sMTIyZTc3NDc1ODQ About...
Prime Article: Research & Publications PA Research & Publications: Quarterly Drug Pipeline -
Specialty Pharmacy Continuum
PA Sub-Categories: GLP-1 Prime Article: In the News -
Forbes
PA Sub-Categories: GLP-1 Prime Article: In the News -
cover image for Cell & Gene Pipeline Outlook: January 2026 Tracking the therapies shaping tomorrow’s care Prime Therapeutics /cell-gene-pipeline-outlook-january-2026 Prime Therapeutics’ Cell & Gene...
Prime Article: Research & Publications PA Research & Publications: Cell & Gene Pipeline Outlook -
Dec. 28, 2024: cosibelimab Checkpoint Therapeutics resubmitted an application for its anti-programmed death ligand-1 (PD-L1) antibody, cosibelimab, for the treatment for adults with metastatic or...
-
Publications Clinical Highlights: April 2025 Your monthly source for drug information highlights. Shortage updates The U.S. Government Accountability Office (GAO) has published a report on drug...
-
cover image Tracking the therapies shaping tomorrow’s care Prime Therapeutics /cell-gene-pipeline-outlook-november-2025 Prime Therapeutics’ Cell & Gene Pipeline Outlook is an industry report that...
Prime Article: Research & Publications PA Research & Publications: Cell & Gene Pipeline Outlook -
Drug Approvals Monthly Update: March 2024 Traditional New drugs 3/04/2024 clobetasol propionate 0.05% The FDA approved the first clobetasol propionate ophthalmic formulations. The 0.05% suspension...